John Hood, CEO, Endeavor BioMedicines discusses the key differences between ENV-101 and currently approved IPF treatments. PE: How does the initiation of the WHISTLE-PF trial fit into Endeavor ...

How improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes Challenges healthcare marketers face in ...

High-Throughput Analysis of Volatile Compounds in Air, Water, and Soil Using SIFT-MS ...

High-Throughput Analysis of Volatile Compounds in Air, Water, and Soil Using SIFT-MS ...

High-Throughput Analysis of Volatile Compounds in Air, Water, and Soil Using SIFT-MS ...

High-Throughput Analysis of Volatile Compounds in Air, Water, and Soil Using SIFT-MS ...

High-Throughput Analysis of Volatile Compounds in Air, Water, and Soil Using SIFT-MS ...

High-Throughput Analysis of Volatile Compounds in Air, Water, and Soil Using SIFT-MS ...

High-Throughput Analysis of Volatile Compounds in Air, Water, and Soil Using SIFT-MS ...

Harpreet Gill, vice president of real-world solutions - project management at ICON, discussesthe progress and challenges in advancing data-driven tools and approaches in decentralized clinical trials, ...

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses regulatory challenges and opportunities that telehealth companies face in 2025. In this ...

High-Throughput Analysis of Volatile Compounds in Air, Water, and Soil Using SIFT-MS ...